Navigation
The Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
Home
Severe Pulmonary Arterial Hypertension Treated with ABI-009, nab-Sirolimus, an mTOR Inhibitor
Next Post
Previous Post
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
April 20, 2019
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Mutational and Biomarker Correlative Analysis of mTOR Pathway Aberrations in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) Treated With
nab
-Sirolimus: Results From AMPECT, an Open-Label Phase 2 Registration Trial
ABI-009,
nab
-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor
nab
-Sirolimus Show Improved Antitumor Activity
nab
-Sirolimus improves mTOR pathway suppression and antitumor activity versus oral mTOR inhibitors in
PTEN
null bladder cancer (UMUC3) and
TSC2
null liver cancer (SNU398) xenografts
Phase I results from a phase 1/2 multi-center study of
nab
-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Synergistic Antitumor Activity of
nab
-Sirolimus in Combination With KRAS Inhibitors Sotorasib and Adagrasib in KRAS G12C Non-Small Cell Lung Cancer and Bladder Cancer Xenografts
Management of adverse events in the AMPECT trial of
nab
-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Patients With Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.